AbbVie’s (ABBV) Outperform Rating Reiterated at Royal Bank Of Canada

AbbVie (NYSE:ABBV)‘s stock had its “outperform” rating reissued by stock analysts at Royal Bank Of Canada in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $280.00 price target on the stock. Royal Bank Of Canada’s price objective would suggest a potential upside of 2.20% from the company’s current price.

Several other brokerages have also recently weighed in on ABBV. UBS Group raised their target price on shares of AbbVie from $260.00 to $275.00 and gave the company a “neutral” rating in a report on Tuesday, October 6th. Leerink Partners boosted their price target on shares of AbbVie from $245.00 to $279.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. Morgan Stanley increased their price objective on shares of AbbVie from $296.00 to $310.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. JPMorgan Chase & Co. raised their price objective on shares of AbbVie from $285.00 to $300.00 and gave the company an “overweight” rating in a report on Thursday, October 8th. Finally, Argus lifted their price objective on shares of AbbVie from $250.00 to $270.00 in a research report on Tuesday, August 4th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and a consensus target price of $277.18.

AbbVie Price Performance

Shares of NYSE ABBV traded down $7.16 during mid-day trading on Tuesday, hitting $273.97. The company had a trading volume of 2,602,160 shares, compared to its average volume of 6,393,934. The company has a market capitalization of $484.04 billion, a PE ratio of 77.44, a price-to-earnings-growth ratio of 1.26 and a beta of 0.24. The business’s 50-day simple moving average is $259.79 and its 200 day simple moving average is $237.39. AbbVie has a 1-year low of $190.75 and a 1-year high of $283.43.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The firm had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. During the same period in the previous year, the firm posted $2.97 EPS. AbbVie’s revenue for the quarter was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, analysts expect that AbbVie will post 13.94 EPS for the current year.

Insider Activity at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. This trade represents a 30.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.06% of the stock is owned by company insiders.

Hedge Funds Weigh In On AbbVie

Several hedge funds have recently made changes to their positions in the company. Burk Holdings LLC acquired a new stake in shares of AbbVie during the second quarter worth $30,000. Marquette Asset Management LLC lifted its position in AbbVie by 52.2% during the second quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock worth $35,000 after buying an additional 48 shares during the period. Abound Financial LLC acquired a new stake in AbbVie in the 4th quarter worth about $32,000. Principia Wealth Advisory LLC grew its holdings in AbbVie by 38.9% in the 2nd quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock valued at $40,000 after buying an additional 44 shares during the period. Finally, Merkkuri Wealth Advisors LLC purchased a new stake in AbbVie in the 1st quarter valued at about $34,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Fresh clinical and regulatory developments are strengthening AbbVie’s growth narrative. Phase 3 data for SKYRIZI and RINVOQ in Crohn’s disease, along with FDA Breakthrough Therapy Designations for temab-A in colorectal and lung cancer, could expand the company’s long-term commercial opportunities. Early obesity data also add potential upside to the pipeline. AbbVie Could Be 44% Below Fair Value on Fresh Pipeline Wins
• Positive Sentiment: Long-term data presented at ACG 2026 continue to support the durability and growth prospects of SKYRIZI and RINVOQ. Analysts expect the two therapies to offset part of Humira’s revenue erosion and drive third-quarter top-line growth. AbbVie Highlights Long-Term SKYRIZI and RINVOQ Data
• Positive Sentiment: Royal Bank of Canada reaffirmed its Outperform rating and assigned a $280 price target, indicating continued confidence in AbbVie’s earnings outlook despite limited near-term upside at current levels.
• Neutral Sentiment: Recent coverage highlights AbbVie as an attractive income stock after market weakness pushed its dividend yield higher. That may support defensive and income-oriented demand, though the yield increase also reflects recent selling pressure. High-Yield Dividend Stocks
• Negative Sentiment: At a lofty valuation following a substantial rally, investors may be taking profits while assessing whether SKYRIZI and RINVOQ can fully replace Humira sales. Rising competition in immunology and the stock’s limited analyst-implied upside are additional near-term headwinds. Will SKYRIZI and RINVOQ Drive AbbVie’s Top-Line Growth?

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.